



HOUSE HEALTH COMMITEE VOTING MEETING

AGENDA

Monday, December 11, 2023

Call of the Chair

Room 515 Irvis Office Building

Harrisburg, PA

-
1. Call to Order
 2. Attendance
 3. Legislation to be Considered:

SB 683 PN 929 (Mastriano) – An Act amending Title 35 (Health and Safety) of the Pennsylvania Consolidated Statutes, in public safety, providing for a requirement that fentanyl and xylazine testing be added to urine drug screens in hospitals.

HOUSE OF REPRESENTATIVES

DEMOCRATIC COMMITTEE BILL ANALYSIS

Bill No:	SB0683 PN0929	Prepared By:	Erika Fricke (412) 422-1774
Committee:	Health	Executive Director:	Erika Fricke
Sponsor:	Mastriano, Doug		
Date:	12/7/2023		

A. Brief Concept

Requires Fentanyl and Xylazine testing be added to urine drug screens in hospitals.

C. Analysis of the Bill

Senate Bill 683 requires fentanyl and xylazine be added to any diagnostic urine drug screening panel conducted in a general acute care hospital. The bill requirement does not apply to specialty hospitals.

Hospitals are permitted to use fentanyl and xylazine test strips, if they do not have equipment to analyze urine screens.

Positive fentanyl and xylazine tests must be deidentified so the patient's name is not connected to the result, and reported to the Department of Health via the National Electronic Disease Surveillance System (PA-NEDSS).

Effective Date:

60 days.

G. Relevant Existing Laws

No existing law requires specific drug screening as part of a urine drug test.

E. Prior Session (Previous Bill Numbers & House/Senate Votes)

N/A

This document is a summary of proposed legislation and is prepared only as general information for use by the Democratic Members and Staff of the Pennsylvania House of Representatives. The document does not represent the legislative intent of the Pennsylvania House of Representatives and may not be utilized as such.

THE GENERAL ASSEMBLY OF PENNSYLVANIA

SENATE BILL

No. 683 Session of 2023

INTRODUCED BY MASTRIANO, BROOKS AND BARTOLOTTA, MAY 15, 2023

SENATOR BROOKS, HEALTH AND HUMAN SERVICES, AS AMENDED, JUNE 20, 2023

AN ACT

1 Amending Title 35 (Health and Safety) of the Pennsylvania
2 Consolidated Statutes, in public safety, providing for
3 miscellaneous provisions.

4 The General Assembly of the Commonwealth of Pennsylvania
5 hereby enacts as follows:

6 Section 1. Title 35 of the Pennsylvania Consolidated
7 Statutes is amended by adding a chapter to read:

CHAPTER 59

MISCELLANEOUS PROVISIONS

10 Sec.

11 5901. (Reserved).

12 5902. Urine drug screening requirement.

13 § 5901. (Reserved).

14 § 5902. Urine drug screening requirement.

15 (a) General rule.--If a urine drug screening is conducted in
16 a general acute care hospital to assist in diagnosing a
17 patient's condition, the urine drug screening shall include
18 testing for fentanyl AND XYLAZINE.

1 (b) Reporting.--If the urine drug screening conducted in
2 accordance with subsection (a) detects fentanyl OR XYLAZINE, the <--
3 hospital shall report the test results, which shall be
4 deidentified, to the Department of Health through PA-NEDSS.

5 (c) Construction.--Nothing in this section shall preclude an
6 acute care hospital without analyzer equipment for urinalysis
7 from utilizing fentanyl test strips OR XYLAZINE TEST STRIPS in <--
8 accordance with the act of April 14, 1972 (P.L.233, No.64),
9 known as The Controlled Substance, Drug, Device and Cosmetic
10 Act.

11 (d) Definitions.--As used in this section, the following
12 words and phrases shall have the meanings given to them in this
13 subsection unless the context clearly indicates otherwise:

14 "Acute care hospital." A facility that provides inpatient
15 and outpatient hospital services and is licensed by the
16 Department of Health as a general or tertiary care hospital. The
17 term does not include a specialty hospital.

18 "Controlled substance." A drug, substance or immediate
19 precursor included in Schedules I through V of The Controlled
20 Substance, Drug, Device and Cosmetic Act.

21 "PA-NEDSS." Pennsylvania's version of the National
22 Electronic Disease Surveillance System.

23 "Urine drug screening." A chemical analysis intended to test
24 a patient for the presence of a controlled substance.

25 Section 2. This act shall take effect in 60 days.